People: Bioheart Inc (BHRT.PK)

BHRT.PK on OTC Markets Group

0.01USD
3:53pm EDT
Change (% chg)

$0.00 (-4.76%)
Prev Close
$0.01
Open
$0.01
Day's High
$0.01
Day's Low
$0.01
Volume
1,257,799
Avg. Vol
3,460,410
52-wk High
$0.03
52-wk Low
$0.00

Search Stocks

Summary

Name Age Since Current Position

William Murphy

91 2010 Chairman of the Board

Mike Tomas

49 2010 President, Chief Executive Officer, Chief Financial Officer, Director

Kristin Comella

38 2013 Chief Scientific Officer, Director

Samuel Ahn

60 2010 Director

Sheldon Anderson

64 2013 Director

Mark Borman

60 2010 Independent Director

Charles Hart

54 2009 Independent Director

Biographies

Name Description

William Murphy

Dr. William P. Murphy, Jr., M.D., is Chairman of the Board of Bioheart, Inc. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation.

Mike Tomas

Mr. Mike Tomas is President, Chief Executive Officer, Chief Financial Officer, Director of Bioheart, Inc. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer and as a director on June 19, 2010. In 2001, Mr. Tomás helped launch The ASTRI Group, an early-stage private equity investment company providing capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.

Kristin Comella

Ms. Kristin C. Comella is Chief Scientific Officer, Director of Bioheart, Inc. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University’s Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.

Samuel Ahn

Dr. Samuel S. Ahn, M.D., is Director of Bioheart, Inc. Dr. Ahn previously served as a member of the Company’s Board of Directors from January 2001 thru September 2008. Dr Ahn was one of the early pioneers in developing the field of endovascular surgery by coordinating and leading the first endovascular training courses in the US and Europe as well as developing some of the endovascular devices and techniques currently in clinical use today. He is a former Professor of Surgery in the Division of Vascular Surgery at UCLA, where he was also the Director of the Endovascular Surgery Program. In 2006 Dr. Ahn founded Vascular Management Associates, Inc., a consulting and management firm that sets up outpatient endovascular centers across the US. VMA has set up 8 such sites to date and is on track to set up two more this year. In 2008, he co-founded Wright-Ahn Technology, LLC, to develop and commercialize endovascular devices. In 2009, he co-founded MediBank International, LLC, a global healthcare IT Company. Dr. Ahn graduated from the University of Texas, Southwestern Medical School in Dallas, and received his general and vascular surgical residency training at UCLA. He also earned his MBA from the UCLA Anderson School of Management in August, 2004. Dr. Ahn sits on five vascular journal editorial boards, and has published over 120 peer-reviewed manuscripts, 50 book chapters, and five textbooks, including the first and definitive textbook on Endovascular Surgery. During the past eighteen years he has consulted for over 50 biomedical companies, both new and established, and has authored over 15 patents.

Sheldon Anderson

Mr. Sheldon T. Anderson has been appointed as Director of Bioheart, Inc., with effect from August 28, 2013. An active community leader, Anderson is the Chair-elect of the Beacon Council, Miami-Dade County's economic development agency. He is a Board member of the Miami-Dade College Foundation, Inc.; Museum of Contemporary Art (MOCA); the New World Symphony; Baptist Health Systems Governing Board and Carrollton School of the Sacred Heart. He is Past Chair and a member of the Advisory Council of the United Way of Miami-Dade County. Anderson is President of the Board of Cleveland Orchestra Miami / Miami Music Association and also serves on the Advisory Board of the University of Miami School of Law for Ethics & Public Service. He is a member of the Orange Bowl Committee and the President's Council of Florida International University. Sheldon holds a degree in International Studies from Ohio State University.

Mark Borman

Mr. Mark P. Borman is Independent Director of Bioheart, Inc. He is a seasoned financial officer with more than 30 years of broad-based financial and investor relations experience. Mr. Borman is a member and Board Leadership Fellow of the National Association of Corporate Directors. In addition to the valuable experience he gained working with entrepreneurs and their startups from 2009 to present, Mr. Borman has experience with global, NASDAQ- and NYSE-listed companies in various executive and financial roles. He is currently the Chief Financial Officer of SheerWind and previously served as Corporate Officer, Treasurer and Vice President of Investor Relations with ADC Telecommunications. During his career, Mr. Borman has held positions with General Instrument Corporation, First Chicago Corporation, FMC Corporation, Price Waterhouse, and KPMG. Mr. Borman received his B.A. in Accounting from Michigan State University and his M.B.A. from the University of Chicago Graduate School of Business. He is a Certified Public Accountant and Chartered Financial Analyst and has experience as an advisor, board member, faculty, speaker, and mentor.

Charles Hart

Mr. Charles A. Hart serves as Independent Director of Bioheart, Inc. Mr. Hart has served as a member of our Board of Directors since May 2009. Mr. Hart has more than 20 years of entrepreneurial experience. Mr. Hart founded Hart Masonry, Inc. in 1986 and has served as its President since then. He is also the Founder and President of Wildridge Enterprises. Mr. Hart is a member of the Board of Directors for Eagle Street Properties LLP.

Basic Compensation

Name Fiscal Year Total

William Murphy

--

Mike Tomas

1,854,480

Kristin Comella

911,518

Samuel Ahn

--

Sheldon Anderson

--

Mark Borman

--

Charles Hart

--
As Of  30 Dec 2014

Options Compensation

Search Stocks